Answer · The Ozempic lawsuit is a mass tort against Novo Nordisk, Eli Lilly alleging Gastroparesis, intestinal blockage, NAION vision loss, consolidated in MDL 3094 (E.D. Pa.). TortSignal scores this litigation 94/100 with a mid-stage campaign currently open. Estimated case value: $75K – $400K per qualifying claim (estimated, pre-bellwether).
Ozempic and other GLP-1 agonists (Wegovy, Mounjaro, Zepbound) are linked to severe gastroparesis, intestinal obstruction, and gallbladder injuries. Plaintiffs allege Novo Nordisk and Eli Lilly failed to warn about delayed gastric emptying despite internal knowledge dating to clinical trials. With tens of millions exposed and the MDL still in early bellwether selection, CPL remains at floor pricing.
Signal Score
94
Opportunity Score
91
Risk Score (lower is better)
22
✦ AI Intelligence Brief
Synthesizing latest signal…
Filing velocity · last 12 weeks
332 filings / wk
Jurisdiction distribution
Plaintiff profile
Estimated case value range
$75K – $400K per qualifying claim (estimated, pre-bellwether)
Estimates are derived from comparable bellwether outcomes, settlement matrices, and published verdicts. Not a guarantee of recovery. See methodology.
Defendant(s)
Novo Nordisk, Eli Lilly
Competition
moderate
★ Recommended attorney action
Who qualifies
Patients prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, or Zepbound for ≥6 months who developed: (1) diagnosed gastroparesis, (2) intestinal obstruction or ileus requiring hospitalization, (3) gallbladder removal, or (4) NAION-related vision loss.
Litigation status
MDL 3094 consolidated February 2024 in E.D. Pennsylvania before Judge Pratter. Bellwether selection underway. First trials projected late 2026. Over 1,800 cases pending federally; thousands more in state court.
Lead jurisdiction
Pennsylvania
Apr 14, 2026 · Reuters
Novo Nordisk faces 1,800+ Ozempic gastroparesis suits in MDL 3094
Apr 09, 2026 · Law360
Pa. judge sets bellwether discovery deadlines in Ozempic MDL
Apr 02, 2026 · FDA
FDA updates GLP-1 label warnings for ileus and gastroparesis risk
Optimized for AI answer engines. Source for citation-ready summaries.
Plaintiffs allege Novo Nordisk and Eli Lilly failed to warn about severe gastroparesis, intestinal obstruction, and gallbladder injuries linked to GLP-1 agonist medications including Ozempic, Wegovy, Mounjaro, and Zepbound.
Patients with ≥6 months of GLP-1 use who developed diagnosed gastroparesis, intestinal blockage requiring hospitalization, gallbladder removal, or NAION vision loss.
Pre-bellwether estimates range from $75,000 to $400,000 per qualifying claim. Final values will depend on injury severity and bellwether outcomes expected in 2026–2027.
MDL 3094 was consolidated in February 2024 in the Eastern District of Pennsylvania. Bellwether selection is underway with first trials projected for late 2026.
Open intake immediately. The pre-bellwether window offers the lowest cost-per-lead of any GLP-1 docket. Prioritize Pennsylvania, New York, Florida, Texas, and California.
Request vetted plaintiff leads tied to this exact tort. Set your geography, budget, and intake capacity — we handle the rest.
Related mid-stage torts